• Subscribe
    • ENG
    • SWE
Cinclus Pharma Cinclus Pharma
  • ENG
  • SWE
  • This is Cinclus Pharma
    • This is Cinclus Pharma

      Company History

      Company strategy

      Work with us

      Open position – Study Physician

      Licensed partners

      Corporate Governance

      Management team

      Board of directors

      General meetings

      Financial reports

    • Company History
    • Company strategy
    • Work with us
    • Licensed partners
    • Corporate Governance
  • Our science
    • Our science

      About Gerd

      Patient Story - Life with GERD

      Patient Story - Everyday life with GERD

      Linaprazan glurate

      PPIs versus P-CABs

      Development strategy

      Clinical development

    • About Gerd
    • Linaprazan glurate
    • Development strategy
    • Clinical development
    • Governance

      Corporate Governance Reports

      General Meetings

      2023

      2022

      Board of directors

      The work of the board

      Board committees

      Management

      Nomination Committee

      Nomination committee instructions

      Remuneration

      Guidelines for remuneration

      Auditing

      Articles of Association

      Internal control

    • Investors

      Reports & Presentations

      Annual Reports

      IPO

      Press releases

  • Media
    • Media

      Press releases

      News

      Subscribe

      Media gallery

      People

      Logotypes

    • Press releases
    • News
    • Subscribe
    • Media gallery
  • Contact
  • Subscribe
  • Home /
  • This is Cinclus Pharma /
  • Corporate Governance /
  • General meetings /
  • 2022
  • Corporate Governance
    • Management team
    • Board of directors
    • General meetings
      • 2023
      • 2022
    • Financial reports
General meetings

General meetings 2022

Extraordinary General Meeting December 2022

  • Notice of EGM December 2022 (sv. kallelse)

  • Power of attorney form (sv. fullmaktsformulär)

  • Advance voting form (sv. förhandsröstningsformulär)

  • The Board of Director's Report, Swedish Companies Act 14:8 (sv. styrelseredogörelse ABL 14 kap 8 §)

  • Auditor's Statement, Swedish Companies Act 14:8 (sv. revisorsyttrande enligt ABL 14 kap 8 §)

  • Terms and Conditions for Cinclus Pharma Holding (publ)’s warrants under QESO 2022
    (sv. Teckningsoptionsvillkor)

Cinclus Pharma

Cinclus Pharma Holding AB (publ)
Kungsbron 1
Level 3, Elevator G
111 22 Stockholm
SWEDEN

Phone: +46 8-133310
E-mail: info@cincluspharma.com

Navigate

  • This is Cinclus Pharma
  • Our science
  • Media
  • Contact

Join our network


© CINCLUS PHARMA 2023Privacy policy